Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia. 1998

S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
Finnish Red Cross Blood Transfusion Service, Helsinki.

Six patients, 4 with acute myeloid leukaemia and 2 with a myelodysplastic syndrome who were refractory to random donor platelet transfusions and alloimmunized to human leucocyte antigens (HLA) and human platelet alloantigens (HPA), were treated with HLA- and HPA-matched platelet transfusions. In all the patients refractoriness and alloantibodies to HLA as well as HPA-1b or HPA-5b were detected simultaneously. Sixty-seven transfusions (445 units) of HLA- and HPA-matched platelets were given and responses to them were, in general, satisfactory in all the patients. No major spontaneous bleeding occurred. Four patients underwent bone marrow transplantation despite alloimmunization. The percentages of platelet transfusion days with a platelet nadir below 20x10(9)/l were 88% for the last 3 random donor platelet transfusions and 39% for the first 3 HLA- and HPA-matched platelet transfusions, respectively (p=0.009, Fisher's exact test). Four patients received also HLA-matched platelets, but responses to them were poor. The small number of transfusions with HLA-matched platelets precluded comparisons to either the random donor or HLA- and HPA-matched platelet transfusions. It seems that HLA- and HPA-alloimmunized patients can be successfully supported with HLA- and HPA-matched platelet concentrates.

UI MeSH Term Description Entries
D007518 Isoantibodies Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. Alloantibodies
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D016824 Antigens, Human Platelet Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy. Antigens, Platelet-Specific,Human Platelet Antigen,Human Platelet Antigens,Platelet Alloantigen,Platelet Alloantigens,Platelet-Specific Antigen,Platelet-Specific Antigens,Alloantigen, Platelet,Alloantigens, Platelet,Antigen, Human Platelet,Antigen, Platelet-Specific,Antigens, Platelet Specific,Platelet Antigen, Human,Platelet Antigens, Human,Platelet Specific Antigen,Platelet Specific Antigens

Related Publications

S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
February 1981, The American journal of medical technology,
S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
January 1998, Vox sanguinis,
S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
August 2002, Transplant immunology,
S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
March 2020, Transfusion,
S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
January 1977, American journal of hematology,
S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
September 1998, Transfusion medicine (Oxford, England),
S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
November 1987, British journal of haematology,
S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
August 2001, Transfusion,
S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
November 2010, Transfusion,
S Kekomäki, and L Volin, and P Koistinen, and E Koivunen, and S Koskimies, and T Ruutu, and T Timonen, and R Kekomäki
January 1983, Transfusion,
Copied contents to your clipboard!